280 related articles for article (PubMed ID: 34281987)
21. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
22. Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation.
Levina V; Su Y; Gorelik E
Clin Dev Immunol; 2012; 2012():173029. PubMed ID: 22654951
[TBL] [Abstract][Full Text] [Related]
23. Epithelial Indoleamine 2,3-Dioxygenase 1 Modulates Aryl Hydrocarbon Receptor and Notch Signaling to Increase Differentiation of Secretory Cells and Alter Mucus-Associated Microbiota.
Alvarado DM; Chen B; Iticovici M; Thaker AI; Dai N; VanDussen KL; Shaikh N; Lim CK; Guillemin GJ; Tarr PI; Ciorba MA
Gastroenterology; 2019 Oct; 157(4):1093-1108.e11. PubMed ID: 31325428
[TBL] [Abstract][Full Text] [Related]
24. Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer.
Kim S; Park S; Cho MS; Lim W; Moon BI; Sung SH
J Cancer; 2017; 8(1):124-130. PubMed ID: 28123606
[TBL] [Abstract][Full Text] [Related]
25. Tobacco carcinogen induces tryptophan metabolism and immune suppression via induction of indoleamine 2,3-dioxygenase 1.
Liang F; Wang GZ; Wang Y; Yang YN; Wen ZS; Chen DN; Fang WF; Zhang B; Yang L; Zhang C; Han SC; Yang FY; Wang D; Liang LJ; Wang Z; Zhao Y; Wang CL; Zhang L; Zhou GB
Signal Transduct Target Ther; 2022 Sep; 7(1):311. PubMed ID: 36068203
[TBL] [Abstract][Full Text] [Related]
26. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Gostner JM; Becker K; Überall F; Fuchs D
Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
[TBL] [Abstract][Full Text] [Related]
27. Preparation and evaluation of L- and D-5-[
Tang T; Gill HS; Ogasawara A; Tinianow JN; Vanderbilt AN; Williams SP; Hatzivassiliou G; White S; Sandoval W; DeMent K; Wong M; Marik J
Nucl Med Biol; 2017 Aug; 51():10-17. PubMed ID: 28511073
[TBL] [Abstract][Full Text] [Related]
28. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
29. Tryptophan metabolism activation by indoleamine 2,3-dioxygenase in adipose tissue of obese women: an attempt to maintain immune homeostasis and vascular tone.
Wolowczuk I; Hennart B; Leloire A; Bessede A; Soichot M; Taront S; Caiazzo R; Raverdy V; Pigeyre M; ; Guillemin GJ; Allorge D; Pattou F; Froguel P; Poulain-Godefroy O
Am J Physiol Regul Integr Comp Physiol; 2012 Jul; 303(2):R135-43. PubMed ID: 22592557
[TBL] [Abstract][Full Text] [Related]
30. Ganoderic acid Me induces the apoptosis of competent T cells and increases the proportion of Treg cells through enhancing the expression and activation of indoleamine 2,3-dioxygenase in mouse lewis lung cancer cells.
Que Z; Zou F; Zhang A; Zheng Y; Bi L; Zhong J; Tian J; Liu J
Int Immunopharmacol; 2014 Nov; 23(1):192-204. PubMed ID: 25138378
[TBL] [Abstract][Full Text] [Related]
31. 4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth.
Panda S; Pradhan N; Chatterjee S; Morla S; Saha A; Roy A; Kumar S; Bhattacharyya A; Manna D
Sci Rep; 2019 Dec; 9(1):18455. PubMed ID: 31804586
[TBL] [Abstract][Full Text] [Related]
32. Hepatic stellate cells increase the immunosuppressive function of natural Foxp3+ regulatory T cells via IDO-induced AhR activation.
Kumar S; Wang J; Thomson AW; Gandhi CR
J Leukoc Biol; 2017 Feb; 101(2):429-438. PubMed ID: 27581538
[TBL] [Abstract][Full Text] [Related]
33. Interferon-γ induces a tryptophan-selective amino acid transporter in human colonic epithelial cells and mouse dendritic cells.
Bhutia YD; Babu E; Ganapathy V
Biochim Biophys Acta; 2015 Feb; 1848(2):453-62. PubMed ID: 25450809
[TBL] [Abstract][Full Text] [Related]
34. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
35. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells.
Curti A; Trabanelli S; Onofri C; Aluigi M; Salvestrini V; Ocadlikova D; Evangelisti C; Rutella S; De Cristofaro R; Ottaviani E; Baccarani M; Lemoli RM
Haematologica; 2010 Dec; 95(12):2022-30. PubMed ID: 20801903
[TBL] [Abstract][Full Text] [Related]
36. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.
Engel JB; Honig A; Kapp M; Hahne JC; Meyer SR; Dietl J; Segerer SE
Arch Gynecol Obstet; 2014 Jan; 289(1):141-7. PubMed ID: 23828443
[TBL] [Abstract][Full Text] [Related]
38. Targeting the IDO1 pathway in cancer: from bench to bedside.
Liu M; Wang X; Wang L; Ma X; Gong Z; Zhang S; Li Y
J Hematol Oncol; 2018 Aug; 11(1):100. PubMed ID: 30068361
[TBL] [Abstract][Full Text] [Related]
39. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
Campesato LF; Budhu S; Tchaicha J; Weng CH; Gigoux M; Cohen IJ; Redmond D; Mangarin L; Pourpe S; Liu C; Zappasodi R; Zamarin D; Cavanaugh J; Castro AC; Manfredi MG; McGovern K; Merghoub T; Wolchok JD
Nat Commun; 2020 Aug; 11(1):4011. PubMed ID: 32782249
[TBL] [Abstract][Full Text] [Related]
40. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
